About
Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain. The company is pioneering a novel approach that targets multiple pain-related mechanisms using a single compound to achieve greater efficacy and safety. Bsense Bios approach is based on the targeting of two cation channels, a ligand-gated and a voltage-gated potassium channel (TRPV1 and Kv7.2/3, respectively), which are co-localized on sensory nociceptive neurons and are widely recognized as prominent players in pain signaling. Bsense is currently assessing in depth the specificity and selectivity in vitro of three lead compounds with the purpose of progressing into in vivo safety and efficacy studies. In addition, the company is performing structural activity relation studies to assess whether they can improve the compounds characteristics to achieve a backup compound series. The company is financed by Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation (JJDC), and the Israel Innovation Authority (IIA). Bsense Bio Therapeutics was founded at the FutuRx biotech incubator.
Funding history · 1 round · $2.7M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Bsense Bio Therapeutics' drug development efforts?
- Bsense Bio Therapeutics is developing small molecules for the treatment of neuropathic pain.
- What is Bsense Bio Therapeutics' novel approach to treating neuropathic pain?
- Bsense Bio Therapeutics is pioneering an approach that targets multiple pain-related mechanisms using a single compound to achieve greater efficacy and safety.
- Which specific biological targets are central to Bsense Bio Therapeutics' approach?
- Bsense Bio Therapeutics' approach targets two cation channels: a ligand-gated channel (TRPV1) and a voltage-gated potassium channel (Kv7.2/3).
- What is the current stage of Bsense Bio Therapeutics' lead compounds?
- Bsense Bio Therapeutics is currently assessing the in vitro specificity and selectivity of three lead compounds, with the goal of progressing to in vivo safety and efficacy studies.
- When was Bsense Bio Therapeutics founded?
- Bsense Bio Therapeutics was founded in September 2018.
- Which investors participated in Bsense Bio Therapeutics' Seed funding round?
- Bsense Bio Therapeutics' Seed round investors include Takeda Ventures Inc, OrbiMed Israel Partners, Johnson & Johnson Innovation (JJDC), and the Israel Innovation Authority (IIA).
- What was the total amount raised by Bsense Bio Therapeutics in its Seed round?
- Bsense Bio Therapeutics raised a total of $2,700,000 in its Seed funding round in September 2018.
- Where was Bsense Bio Therapeutics founded?
- Bsense Bio Therapeutics was founded at the FutuRx biotech incubator.
- What is the approximate employee count for Bsense Bio Therapeutics?
- Bsense Bio Therapeutics has an employee count in the range of 1-10, with an exact count of 6 employees.